97175 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy
#2702THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#2703Targeted human-interferon fusion proteins
#2704Use of HLA-B27 homodimers for cancer treatment
#2705USE OF PLINABULIN IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS
#2706Anti-PD-L1 antibodies and diagnostic uses thereof
#2707Bispecific binding proteins and uses thereof
#2708Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
#2709Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof
#2710Fluorocyclopentenylcytosine methods of use
#2711Pharmaceutical composition for preventing or treating cancer and method using thereof
#2712METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS
#2713Antibodies against TIM3 and uses thereof
#2714Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
#2715TREATMENT OF CANCER BY MANIPULATION OF COMMENSAL MICROFLORA
#2716Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
#2717Phage-displayed single-chain variable fragment library
#2718Methods of increasing delivery of anti-cancer agents to targets
#2719TARGETED TGFß INHIBITION
#2720PD-L1-specific antibodies and methods of using the same
#2721Anti-PD-L1 antibodies
#2722Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
#2723Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
#2724SELF-BUFFERING PROTEIN FORMULATIONS
#2725Multispecific and multifunctional molecules and uses thereof
#2726Formulation of curcumin and anti-PD-1 antibody
#2727Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
#2728USE OF BLOCKING-REAGENTS FOR REDUCING UNSPECIFIC T CELL-ACTIVATION
#2729Anti-B7H3 binding compounds and uses thereof
#2730Antibodies and immunocytokines
#2731Compositions and methods for T cell delivery of therapeutic molecules
#2732PD-L1 specific monoclonal antibodies for disease treatment and diagnosis
#2733Anti-B7-H3 antibodies and antibody drug conjugates
#2734Combinatorial androgen deprivation with an androgen receptor vaccine
#2735Histochemical assay for evaluating expression of programmed death ligand 1 (PD-L1)
#2736COMBINATION THERAPIES
#2737Methods of treating conditions with antibodies that bind B7-H4
#2738Antibody molecules for cancer treatment
#2739Combination therapies of HDAC inhibitors and PD-L1 inhibitors
#2740COMBINATION THERAPIES
#2741THERAPEUTIC COMBINATIONS AND METHODS FOR TREATING NEOPLASIA
#2742Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
#2743Anti-PD-L1 antibodies
#2744Checkpoint Blockade and Microsatellite Instability
#2745COMPOSITIONS AND METHODS FOR TREATING CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES
#2746Compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodies
#2747Anti-human vista antibodies and use thereof
#2748Anti-human vista antibodies and use thereof
#2749ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#2750ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#2751ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#2752Anti-human vista antibodies and use thereof
#2753Treatment Methods for Rheumatoid Arthritis
#2754Combination therapies
#2755Neutralization of inhibitory pathways in lymphocytes
#2756Anti PD-L1 conjugates for treating tumors
#2757COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND PD-1 AXIS BINDING ANTAGONISTS
#2758Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
#2759COMBINATION THERAPIES OF ALK INHIBITORS
#2760METHODS FOR IDENTIFYING PATIENTS RESPONSIVE TO ANTI-PD-L1 ANTIBODY THERAPY
#2761Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
#2762METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND IL-17 BINDING ANTAGONISTS
#2763Method of treating CD155 expressing cancers
#2764Chemically-locked bispecific antibodies
#2765Anti-PD-L1 antibodies and uses thereof
#2766Anti-PD-L1 antibodies and uses thereof
#2767RNA viruses expressing IL-12 for immunovirotherapy
#2768T-cell redirecting bispecific antibodies for treatment of disease
#2769METHODS AND COMPOSITIONS FOR CANCER TREATMENT AND TREATMENT SELECTION
#2770ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY
#2771Enhancing the therapeutic activity of immune checkpoint inhibitor
#2772Antibodies, compositions, and uses
#2773Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
#2774Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
#2775Method of identifying anti-VISTA antibodies
#2776Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
#2777Soluble CD80 as a therapeutic to reverse immune suppression in cancer patients
#2778Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
#2779COMBINATION THERAPIES
#2780Anti-CD3 antibodies and methods of use
#2781B7-H3 AND B7-H4, NOVEL IMMUNOREGULATORY MOLECULES
#2782Anti-PD-L1 antibodies
#2783Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens
#2784MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS
#2785Multivalent and multispecific 41BB-binding fusion proteins
#2786Multi-chain polypeptide-containing tri-specific binding molecules
#2787COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT
#2788BSL2v2c2-Ig polypeptides
#2789Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
#2790THERAPEUTIC AGENT FOR SOLID CANCER
#2791Methods and Compositions for the Generation and Maintenance of Regulatory T Cells
#2792Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#2793HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)
#2794Anti-canine PD-1 antibody or anti-canine PD-L1 antibody
#2795GALECTIN IMMUNOTHERAPY
#2796Method for identifying antigen-specific antibodies in primate
#2797B7-H3 IN CANCER
#2798Method for reducing side effects of immune checkpoint control agent
#2799Combination of oncolytic virus with immune checkpoint modulators
#2800Chemically-locked bispecific antibodies
#2801Targeted binding agents against B7-H1
#2802CD3-binding molecules capable of binding to human and non-human CD3
#2803Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
#2804Compositions and methods to activate or inhibit toll-like receptor signaling
#2805Use of vista agonists and antagonists to suppress or enhance humoral immunity
#2806Activating JAK Kinase Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
#2807ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS
#2808VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER
#2809Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
#2810Anti-PD-L1 antibodies, compositions and articles of manufacture
#2811COMBINATORIAL IMMUNOTHERAPY FOR PANCREATIC CANCER TREATMENT
#2812Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
#2813β-glucan methods and compositions that affect the tumor microenvironment
#2814Single domain binding molecule
#2815Combination therapy with glutaminase inhibitors and immuno-oncology agents
#2816Distinguishing antagonistic and agonistic anti B7-H1 antibodies
#2817Anti-tigit antibodies and methods of use
#2818COMPOSITIONS AND METHODS FOR TARGETING A PATHWAY
#2819Anti-B7-H3 antibodies and diagnostic uses thereof
#2820Engineered antibody-interferon mutant fusion molecules
#2821Targeted human-interferon fusion proteins
#2822Proteins specific for BAFF and B7RP1
#2823Enhancing the therapeutic activity of an immune checkpoint inhibitor
#2824PD-L1 antibodies
#2825BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#2826COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
#2827Anti-vista antibodies and fragments
#2828Humanized antibodies against CEACAM1
#2829Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors
#2830Method of treating cancer using immune checkpoint inhibitor
#2831Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#2832Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
#2833Checkpoint inhibitor and a whole cell for use in cancer therapy
#2834T-cell redirecting bispecific antibodies for treatment of disease
#2835COMBINATION OF IMMUNOMODULATORY AGENT WITH PD-1 or PD-L1 CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER
#2836CD86 ANTAGONIST MULTI-TARGET BINDING PROTEINS
#2837Fluorocyclopentenylcytosine methods of use
#2838METHODS OF TREATING HER2-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-HER2 ANTIBODIES
#2839Methods for the treatment of vascularizing cancers
#2840PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
#2841SUPERANTIGEN POST-EXPOSURE THERAPY
#2842Tight-binding agents and uses thereof
#2843Anti-C10orf54 antibodies and uses thereof
#2844Anti-CLL-1 antibodies and methods of use
#2845ANTI B7-H3 ANTIBODY
#2846Humanized and affinity matured antibodies to FcRH5 and methods of use
#2847Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
#2848Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
#2849Treatment of cancer by manipulation of commensal microflora
#2850THERAPEUTIC COMBINATIONS AND METHODS FOR TREATING NEOPLASIA
#2851Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#2852Immunomodulatory agents
#2853B7-related nucleic acids and polypeptides useful for immunomodulation
#2854COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF MELANOMA USING PD-L1 ISOFORMS
#2855SELF-BUFFERING PROTEIN FORMULATIONS
#2856VISTA antagonist and methods of use
#2857Anti-PDL1 antibody formulations
#2858Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
#2859SRM Assay for PD-L1
#2860Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
#2861Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
#2862Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
#2863Combination of immunotherapy with local chemotherapy for the treatment of malignancies
#2864Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands
#2865Kynurenine Pathway Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
#2866METHOD FOR PREDICTING DEVELOPMENT OF MELANOMA BRAIN METASTASIS
#2867Amino acid sequences that modulate the interaction between cells of the immune system
#2868Amino acid sequences that modulate the interaction between cells of the immune system
#2869Antibody-drug conjugate
#2870Anti-PD-L1 monoclonal antibodies and fragments thereof
#2871Antibodies reactive with B7-H3 and uses thereof
#2872Stable subcutaneous protein formulations and uses thereof
#2873Methods of treating cancers using PD-1 axis binding antagonists and taxanes
#2874Methods for treating cancer in patients with elevated levels of BIM
#2875In vivo individualized systemic immunotherapeutic method and device
#2876Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
#2877Methods for treating hematologic cancers
#2878Anti-B7-H1 antibodies for treating tumors
#2879Isolated B7-H4 specific compositions and methods of use thereof
#2880Biomarkers and methods of treating PD-1 and PD-L1 related conditions
#2881NUCLEIC ACID ENCODING ANTI-PD-L1 ANTIBODIES
#2882Cancer therapy via a combination of epigenetic modulation and immune modulation
#2883Screening method for inhibitors of binding of zBR7R1 to CD155
#2884COMBINED PHARMACEUTICAL COMPOSITION
#2885SIRP-α immunoglobulin fusion proteins
#2886T-cell redirecting bispecific antibodies for treatment of disease
#2887Antibodies to TIGIT
#2888Combination Therapy For Treatment Of Disease
#2889Synthetic library of specific binding molecules
#2890Human monoclonal antibodies to O8E
#2891Regulatory T cell mediator proteins and uses thereof
#2892Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists
#2893Anti-B7-H4 antibodies and immunoconjugates
#2894Immunopotentiative composition
#2895RECEPTORS FOR B7-H4
#2896Human anti-B7RP1 neutralizing antibodies
#2897Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
#2898Single domain binding molecule
#2899COMPOSITIONS AND METHODS FOR TREATING CANCER
#2900ANTIBODIES AND OTHER MOLECULES THAT BIND B7-H1 AND PD-1
#2901Isolated antibody
#2902Antibody molecules to PD-L1 and uses thereof
#2903Anti-B7-H5 antibodies and their uses
#2904B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE
#2905B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE
#2906Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2907VISTA Antagonist and Methods of Use
#2908Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
#2909Isolation of therapeutic target specific VNAR domains to ICOSL
#2910Biomarkers for acute myeloid leukemia
#2911COMBINATION THERAPY FOR PD-L1 NEGATIVE TUMORS
#2912Administration of kynurenine depleting enzymes for tumor therapy
#2913Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
#2914B7-H4 EXPRESSION ON TUMOR VASCULATURE
#2915Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
#2916T REGULATORY CELLS AND USES THEREOF
#2917B7-H4 fusion proteins and methods of use thereof
#2918ANTAGONISTS OF PDL-1 AND PD-1 FOR THE TREATMENT OF HPV-NEGATIVE CANCERS
#2919Proteins specific for BAFF and B7RP1 and uses thereof
#2920Methods of modulating immune function
#2921Anti-H7CR antibodies
#2922Anti-B7-H4 antibodies and immunoconjugates
#2923NEWCASTLE DISEASE VIRUSES AND USES THEREOF
#2924ANTI-PD-L1 ANTIBODIES AND DIAGNOSTIC USES THEREOF
#2925Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
#2926HHLA2 as a novel inhibitor of human immune system and uses thereof
#2927Methods of Modulating Immune Function
#2928Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
#2929IL-15-based molecules and methods of use thereof
#2930GLA monotherapy for use in cancer treatment
#2931Antibodies that bind to human programmed death ligand 1 (PD-L1)
#2932Antibody-drug conjugate produced by binding through linker having hydrophilic structure
#2933PD-L1 antibodies and uses thereof
#2934AGENTS FOR TREATING TUMORS, USE AND METHOD THEREOF
#2935Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
#2936Anti-B7 H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
#2937ANTI-PD-L1 ANTIBODIES AND ARTICLES OF MANUFACTURE
#2938Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists
#2939Anti-human B7-H4 antibodies and their uses
#2940OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF
#2941Agents that modulate immune cell activation and methods of use thereof
#2942Antibody-drug conjugate
#2943Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
#2944Human monoclonal anti-PD-L1 antibodies and methods of use
#2945AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM
#2946Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
#2947STIMULATING BONE FORMATION BY INHIBITION OF CD28 CO-STIMULATION
#2948Targeted TGFβ inhibitors
#2949Methods and products related to targeted cancer therapy
#2950Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#2951Human antibodies to PD-L1
#2952Human antibodies to PD-1
#2953Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
#2954HIGH PRESSURE REFOLDING OF MONOCLONAL ANTIBODY AGGREGATES
#2955B7 family member zB7H6 and related compositions and methods
#2956OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE
#2957Anti-CD3 antibodies and methods of use
#2958Anti-B7-H6 antibody, fusion proteins, and methods of using the same
#2959COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#2960BTLA antibodies and uses thereof
#2961Methods of treating tumors with engineered antibody-interferon mutant fusion molecules
#2962Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
#2963CTLA4 fusion proteins for the treatment of diabetes
#2964Immunopotentiative composition
#2965Combination therapy of antibodies against human CSF-1R and antibodies agains human PD-L1
#2966Treatment methods for rheumatoid arthritis
#2967Monoclonal antibodies that bind B7H6 and uses thereof
#2968METHOD TO IMPROVE THE IMMUNE FUNCTION OF T CELLS
#2969Anti-B7-H4 antibodies and their uses
#2970Targeted binding agents against B7-H1
#2971Targeted human-interferon fusion proteins
#2972Vista modulators for diagnosis and treatment of cancer
#2973Anti-PD-L1 antibodies and uses thereof
#2974B7-H6 therapeutically active monoclonal antibody against B7-H6 polypeptide
#2975Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
#2976PD-1 antibodies and PD-L1 antibodies and uses thereof
#2977B7-H3L cell surface antigen and antibodies that bind thereto
#2978Antibodies reactive with B7-H3 and uses thereof
#2979Anti-B7-H4 antibodies and immunoconjugates
#2980Immunopotentiative composition
#2981Isolated B7-H4 specific compositions and methods of use thereof
#2982Proteins specific for BAFF and B7RP1
#2983Isolated B7-H4 specific compositions and methods of use thereof
#2984Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
#2985B7-H3 and B7-H4, novel immunoregulatory molecules
#2986Polynucleotides encoding BSL2v2c2
#2987Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
#2988Polynucleotides encoding BSL2v2c2-Ig
#2989IMMUNOTHERAPY OF B CELL MALIGNANCIES AND AUTOIMMUNE DISEASES USING UNCONJUGATED ANTIBODIES AND CONJUGATED ANTIBODIES AND ANTIBODY COMBINATIONS AND FUSION PROTEINS
#2990Human monoclonal antibodies to O8E
#2991VISTA modulators for diagnosis and treatment of cancer
#2992CD3-binding molecules capable of binding to human and non-human CD3
#2993Dendritic cell co-stimulatory molecules
#2994Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
#2995VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
#2996T-cell redirecting bispecific antibodies for treatment of disease
#2997Antibodies and other molecules that bind B7-H1 and PD-1
#2998Regulatory T cell mediator proteins and uses thereof
#2999Antibodies to human B7x for treatment of metastatic cancer
#3000B7-H7 ANTIBODIES AND METHOD OF USE